Literature DB >> 10331696

Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study.

G Tedeschi1, S Bonavita, T K Banerjee, A Virta, R Schiffmann.   

Abstract

BACKGROUND: The in vivo determination of parenchymal involvement is important to evaluate disease burden. Proton MRS imaging (1H-MRSI) permits simultaneous measurement of N-acetylaspartate (NA), a putative neuron-specific molecule, choline-containing compounds, creatine-phosphocreatine, and lactate from four 15-mm slices divided into 0.84-mL single-volume elements.
OBJECTIVE: To assess the cortical and subcortical neuropathology in Fabry disease (FD).
METHODS: Regions of interest (ROIs) were selected from several cortical and subcortical locations in nine FD patients. Mean ROI metabolite ratios were compared with control values.
RESULTS: FD patients showed a widespread pattern of cortical and subcortical NA reduction. Seven patients showed discrete MRI abnormalities consisting of white matter hyperintensities or basal ganglia infarcts.
CONCLUSION: We found diffuse neuronal involvement in FD extending beyond the areas of MRI-visible cerebrovascular abnormalities. 1H-MRSI may become useful in therapeutic trials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331696     DOI: 10.1212/wnl.52.8.1663

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

1.  MR imaging and proton spectroscopy of neuronal injury in late-onset GM2 gangliosidosis.

Authors:  Matilde Inglese; Annette O Nusbaum; Gregory M Pastores; John Gianutsos; Edwin H Kolodny; Oded Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

2.  [Fabry's disease: new therapeutic options for this lysosomal storage disorder].

Authors:  A J Grau; M Schwaninger; H H Goebel; M Beck
Journal:  Nervenarzt       Date:  2003-05-20       Impact factor: 1.214

Review 3.  Stroke and Fabry disease.

Authors:  Miguel Viana-Baptista
Journal:  J Neurol       Date:  2011-10-27       Impact factor: 4.849

4.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

5.  Diffusion tensor imaging and brain volumetry in Fabry disease patients.

Authors:  Teemu Paavilainen; Virva Lepomäki; Jani Saunavaara; Ronald Borra; Pirjo Nuutila; Ilkka Kantola; Riitta Parkkola
Journal:  Neuroradiology       Date:  2013-01-05       Impact factor: 2.804

6.  Quantitative in vivo brain magnetic resonance spectroscopic monitoring of neurological involvement in mucopolysaccharidosis type II (Hunter Syndrome).

Authors:  James E Davison; Christian J Hendriksz; Yu Sun; Nigel P Davies; Paul Gissen; Andrew C Peet
Journal:  J Inherit Metab Dis       Date:  2010-10-01       Impact factor: 4.982

7.  Diffuse structural and metabolic brain changes in Fabry disease.

Authors:  Silvia Marino; Walter Borsini; Susanna Buchner; Marzia Mortilla; Maria L Stromillo; Marco Battaglini; Antonio Giorgio; Placido Bramanti; Antonio Federico; Nicola De Stefano
Journal:  J Neurol       Date:  2006-03-20       Impact factor: 4.849

8.  T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease.

Authors:  Jun-ichi Takanashi; A James Barkovich; William P Dillon; Elliott H Sherr; Kimberly A Hart; Seymour Packman
Journal:  AJNR Am J Neuroradiol       Date:  2003-05       Impact factor: 3.825

9.  CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy.

Authors:  L Jardim; L Vedolin; I V D Schwartz; M G Burin; C Cecchin; L Kalakun; U Matte; F Aesse; C Pitta-Pinheiro; J Marconato; R Giugliani
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

10.  Voxel based analyses of diffusion tensor imaging in Fabry disease.

Authors:  J Albrecht; P R Dellani; M J Müller; I Schermuly; M Beck; P Stoeter; A Gerhard; A Fellgiebel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04-20       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.